Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to $10.4 million.

  • Avalo Therapeutics' Total Non-Current Liabilities fell 8373.83% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 8373.83%. This contributed to the annual value of $9.6 million for FY2024, which is 1770.49% up from last year.
  • Per Avalo Therapeutics' latest filing, its Total Non-Current Liabilities stood at $10.4 million for Q3 2025, which was down 8373.83% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Total Non-Current Liabilities registered a high of $219.1 million during Q1 2024, and its lowest value of $8.1 million during Q4 2023.
  • In the last 5 years, Avalo Therapeutics' Total Non-Current Liabilities had a median value of $36.8 million in 2022 and averaged $44.6 million.
  • In the last 5 years, Avalo Therapeutics' Total Non-Current Liabilities soared by 56401.04% in 2024 and then crashed by 9627.28% in 2025.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Total Non-Current Liabilities stood at $54.8 million in 2021, then dropped by 28.05% to $39.5 million in 2022, then crashed by 79.37% to $8.1 million in 2023, then grew by 17.7% to $9.6 million in 2024, then increased by 8.49% to $10.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $10.4 million for Q3 2025, versus $11.7 million for Q2 2025 and $8.2 million for Q1 2025.